Dr. Ranee Mehra, MD
Claim this profileUniversity of Maryland/Greenebaum Cancer Center
Expert in Skin Cancer
Expert in Squamous Cell Carcinoma
28 reported clinical trials
56 drugs studied
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
metastatic
2Squamous Cell Carcinoma
Global LeaderStage IV
Stage III
metastatic
Affiliated Hospitals
Clinical Trials Ranee Mehra, MD is currently running
ADT + Pembrolizumab
for Salivary Gland Cancer
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Recruiting1 award Phase 221 criteria
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
More about Ranee Mehra, MD
Clinical Trial Related6 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Ranee Mehra, MD has experience with
- Pembrolizumab
- Cisplatin
- Binimetinib
- Ipatasertib
- Palbociclib
- Evorpacept
Breakdown of trials Ranee Mehra, MD has run
Skin Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ranee Mehra, MD specialize in?
Ranee Mehra, MD focuses on Skin Cancer and Squamous Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ranee Mehra, MD currently recruiting for clinical trials?
Yes, Ranee Mehra, MD is currently recruiting for 11 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Ranee Mehra, MD has studied deeply?
Yes, Ranee Mehra, MD has studied treatments such as Pembrolizumab, Cisplatin, Binimetinib.
What is the best way to schedule an appointment with Ranee Mehra, MD?
Apply for one of the trials that Ranee Mehra, MD is conducting.
What is the office address of Ranee Mehra, MD?
The office of Ranee Mehra, MD is located at: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland 21201 United States. This is the address for their practice at the University of Maryland/Greenebaum Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.